Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial)

Trial Profile

Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs Avelumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms ICONIC
  • Most Recent Events

    • 05 Jun 2018 According to trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology, an interim analysis will assess safety and Mandard tumour regression grading (TRG) after 15 patients become evaluable.If greater than or equal to 5 patients achieve TRG 1-3 the trial will expand to 40 patients.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 08 Feb 2018 Planned number of patients changed from 38 to 40.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top